Rosmarinic Acid Induces Proliferation Suppression of Hepatoma Cells Associated with NF-κB Signaling Pathway

Yanjun An, Jiandong Zhao, Yourui Zhang, Wen Wu, Jiangtao Hu, Haosen Hao, Yu Qiao, Ying Tao, Liping AnResearch 2020 · DOI

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, characterized by high metastatic potential and resistance to standard therapies. This study investigates the therapeutic potential of Rosmarinic acid (RA), a natural phenolic compound, against the human hepatoma cell line HepG2. Our findings demonstrate that RA significantly suppresses cell proliferation, migration, and invasion while inducing apoptosis. These effects are mediated through the inhibition of the PI3K/Akt/NF-κB signaling pathway, likely initiated by RA's role as a Fyn inhibitor. These results suggest that RA is a promising drug candidate for the treatment of HCC.

Introduction

Hepatocellular carcinoma (HCC) is notoriously difficult to treat due to its aggressive nature and late-stage diagnosis. While natural compounds have long been explored for their antioxidant and anti-inflammatory properties, their specific molecular mechanisms in oncology require rigorous validation. Rosmarinic acid (RA), found in common herbs like rosemary and peppermint, has emerged as a potential anti-cancer agent. Previous homology modeling suggested RA acts as an inhibitor of Fyn, a protein kinase that regulates the PI3K/Akt pathway—a signaling axis frequently hijacked by cancer cells to promote survival and metastasis.

Methods

The study utilized the human hepatoma cell line HepG2 and Normal Human Astrocytes (NHA) as a control for toxicity.

  • Cell Viability: Assessed using CCK-8 and XTT assays across various RA concentrations (0–400 µM).
  • Metastatic Potential: Evaluated via wound healing (migration) and Matrigel invasion assays.
  • Apoptosis Analysis: Programmed cell death was visualized using TUNEL staining and DAPI, while protein expression of Bax, Bcl-2, and cleaved caspase-3 was analyzed via Western Blotting.
  • Signaling Pathway Analysis: Western Blotting was used to quantify the expression of PI3K, Akt, and NF-κB p65.

Results

Selective Cytotoxicity and Reduced Proliferation

RA treatment resulted in a dose- and time-dependent decrease in HepG2 cell viability. Importantly, RA showed minimal toxicity toward normal human astrocytes (NHA), suggesting a favorable therapeutic window for cancer treatment.

Figure 1: Chemical structure of RA and its effects on cell viability and migration. (A) RA structure. (B-D) Cell viability assays showing dose-dependent inhibition in HepG2 cells vs. NHA. (E-F) Wound healing assay demonstrating reduced migration.

Inhibition of Migration and Invasion

The metastatic capabilities of HepG2 cells were significantly impaired by RA. In wound healing assays, the control group achieved 60% wound closure within 48 hours, whereas cells treated with 400 µM RA reached only 20% closure. Furthermore, RA reduced cell invasion by 76.4% at the highest concentration. This was accompanied by a downregulation of Matrix Metalloproteinases (MMP-2 and MMP-9), the enzymes responsible for degrading the extracellular matrix during cancer spread.

Induction of Apoptosis

TUNEL staining confirmed that RA induces apoptosis in a dose-dependent manner. Molecular analysis revealed a shift in the balance of apoptotic regulators: the expression of the pro-apoptotic protein Bax increased, while the anti-apoptotic protein Bcl-2 decreased. The resulting Bax/Bcl-2 ratio increased by 156.3% at 400 µM RA. Additionally, increased levels of cleaved caspase-3 confirmed the activation of the execution phase of apoptosis.

Modulation of the PI3K/Akt/NF-κB Pathway

The study confirmed that RA effectively "mutes" the survival signals used by hepatoma cells. RA treatment led to a dramatic decrease in the phosphorylation of Akt and the expression of NF-κB p65 (up to a 56% reduction). By inhibiting this pathway, RA prevents the nuclear translocation of NF-κB, thereby suppressing the transcription of genes involved in tumor growth and survival.

Conclusion

Rosmarinic acid effectively inhibits the progression of HCC in vitro by targeting the PI3K/Akt/NF-κB signaling pathway. By inducing apoptosis and suppressing the machinery required for migration and invasion, RA demonstrates significant potential as a therapeutic agent. Future research utilizing in vivo models is necessary to evaluate the bioavailability and clinical efficacy of RA in treating liver cancer.

Summary updated

Abstract

Abstract Background: Rosmarinic acid (RA) is a natural phenolic compound that acts as a Fyn inhibitor by 53 homology modeling of the human Fyn structure. Therefore, the apoptosis mechanism related to NF-κB signaling pathway induced by RA in HepG2 was investigated. Methods: The cell growth, apoptosis, and proliferation of HepG2 regulated by various concentrations of RA were studied. The proteins expression of MMP-2, MMP-9, PI3K, AKT, NF-κB, and apoptosis-related proteins Bax, Bcl-2, cleaved caspase-3 were detected. Results: RA significantly reduced proliferation rates, inhibited migration and invasion, and decreased the expressions of invasion-related factors, such as matrix metalloproteinase (MMP)-2 and MMP-9. TUNEL staining revealed that RA resulted in a dose-dependent increase of HepG2 cell apoptosis. In line with this finding, the expression of apoptosis suppressor protein Bcl-2 was downregulated and that of the pro-apoptotic proteins Bax and cleaved caspase-3 was increased. In addition, we found that the phosphatidylinositol 3-kinase (PI3K)/Akt/nuclear factor kappa B (NF-κB) signaling pathway was involved in RA-mediated inhibition of HepG2 cell metastasis. Conclusion: Our study identified that RA as a drug candidate for the treatment of HCC.
BibTeX
@inproceedings{an2020rosmarinic,
  author = {Yanjun An and Jiandong Zhao and Yourui Zhang and Wen Wu and Jiangtao Hu and Haosen Hao and Yu Qiao and Ying Tao and Liping An},
  title = {{Rosmarinic Acid Induces Proliferation Suppression of Hepatoma Cells Associated with NF-κB Signaling Pathway}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-100929/v1},
}
Figure